DK2869841T3 - Hidtil ukendte prime-boosting-regimer, der omfatter immunogene polypeptider kodet af polynukleotider - Google Patents

Hidtil ukendte prime-boosting-regimer, der omfatter immunogene polypeptider kodet af polynukleotider Download PDF

Info

Publication number
DK2869841T3
DK2869841T3 DK13734111.1T DK13734111T DK2869841T3 DK 2869841 T3 DK2869841 T3 DK 2869841T3 DK 13734111 T DK13734111 T DK 13734111T DK 2869841 T3 DK2869841 T3 DK 2869841T3
Authority
DK
Denmark
Prior art keywords
polynucleotides
polypeptides encoded
immunogenic polypeptides
boosting regimens
novel prime
Prior art date
Application number
DK13734111.1T
Other languages
English (en)
Inventor
Alfredo Nicosia
Alessandra Vitelli
Ricardo Cortese
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Application granted granted Critical
Publication of DK2869841T3 publication Critical patent/DK2869841T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK13734111.1T 2012-07-05 2013-07-05 Hidtil ukendte prime-boosting-regimer, der omfatter immunogene polypeptider kodet af polynukleotider DK2869841T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/063196 WO2014005643A1 (en) 2012-07-05 2012-07-05 Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
PCT/EP2013/064286 WO2014006191A1 (en) 2012-07-05 2013-07-05 Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides

Publications (1)

Publication Number Publication Date
DK2869841T3 true DK2869841T3 (da) 2021-10-25

Family

ID=48746554

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13734111.1T DK2869841T3 (da) 2012-07-05 2013-07-05 Hidtil ukendte prime-boosting-regimer, der omfatter immunogene polypeptider kodet af polynukleotider

Country Status (19)

Country Link
US (3) US20150209420A1 (da)
JP (1) JP6244358B2 (da)
KR (1) KR20150038010A (da)
CN (1) CN104780937A (da)
AU (1) AU2013285398A1 (da)
BR (1) BR112014033077A2 (da)
CA (1) CA2878367A1 (da)
DK (1) DK2869841T3 (da)
EA (1) EA201492230A1 (da)
ES (1) ES2895070T3 (da)
HU (1) HUE056675T2 (da)
IL (1) IL236414A0 (da)
IN (1) IN2014KN03063A (da)
LT (1) LT2869841T (da)
MX (1) MX365391B (da)
PT (1) PT2869841T (da)
SG (1) SG11201408746XA (da)
WO (2) WO2014005643A1 (da)
ZA (1) ZA201500102B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014259474B2 (en) 2013-04-25 2018-09-13 Janssen Vaccines & Prevention B.V. Stabilized soluble prefusion RSV F polypeptides
US11571472B2 (en) * 2014-06-13 2023-02-07 Glaxosmithkline Biologicals Sa Immunogenic combinations
FI3656395T3 (fi) 2014-09-03 2024-02-05 Bavarian Nordic As Menetelmiä ja koostumuksia suojaavan immuniteetin aikaansaamiseksi filovirusinfektiota vastaan
JP2017527564A (ja) 2014-09-03 2017-09-21 バヴァリアン ノルディック エー／エス 免疫応答の増進を目的とする方法及び組成物
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
JP6893177B2 (ja) 2015-05-15 2021-06-23 キュアバック アーゲー 少なくとも１つのｍＲＮＡコンストラクトの投与を含むプライムブーストレジメン（ＰＲＩＭＥ−ＢＯＯＳＴ ＲＥＧＩＭＥＮＳ）
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
CA2991002C (en) 2015-07-07 2023-11-28 Janssen Vaccines & Prevention B.V. Vaccine against rsv
KR102500970B1 (ko) 2016-04-05 2023-02-17 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
PT3439672T (pt) 2016-04-05 2021-02-24 Janssen Vaccines & Prevention Bv Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv
MX2018013340A (es) * 2016-05-02 2019-08-21 Janssen Vaccines & Prevention Bv Combinaciones de vacunas terapeuticas para el vph.
KR102421049B1 (ko) 2016-05-30 2022-07-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합-전 rsv f 단백질
WO2018011768A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines And Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
SG11201908999QA (en) 2017-04-04 2019-10-30 Univ Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
US11173204B2 (en) 2017-04-06 2021-11-16 Janssen Vaccines & Prevention B.V. MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
WO2018210871A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
US11229695B2 (en) 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
CA3076026C (en) * 2017-10-25 2024-10-01 Nouscom Ag EUKARYOTIC CELL LINE
WO2019094396A1 (en) * 2017-11-07 2019-05-16 Nektar Therapeutics Immunotherapeutic combination for treating cancer
CA3095216A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
CN113164583A (zh) 2018-11-13 2021-07-23 扬森疫苗与预防公司 稳定的融合前rsv f蛋白
GB201910794D0 (en) * 2019-07-29 2019-09-11 Pirbright Inst Vaccine
CN112220921B (zh) * 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗
CN117304280B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511845B1 (en) * 1992-08-07 2003-01-28 Alan R. Davis Methods for producing an immune response against HIV-1
US6180398B1 (en) * 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
CA2526120A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
SI2163260T1 (sl) 2004-01-23 2017-07-31 Msd Italia S.R.L. Nosilci šimpanzjih adenovirusnih cepiv
EP2001516A4 (en) * 2006-03-10 2010-04-28 Univ California VACCINATES AGAINST PERSISTENT OR LATENT INFECTIONS THREADING VIRUSES
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
WO2008085502A2 (en) * 2007-01-05 2008-07-17 Inseron, Inc. A green fluorescent protein optimized for expression with self-cleaving polypeptides
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
US20090092635A1 (en) * 2007-08-17 2009-04-09 Wyeth Heterologous prime-boost immunization regimen
CL2007002710A1 (es) * 2007-09-20 2008-01-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
US7863425B2 (en) * 2007-09-26 2011-01-04 Cornell University Compositions and methods for inhibiting Yersinia pestis infection
GB0823497D0 (en) * 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
CA2749325C (en) 2009-02-02 2021-03-30 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
AU2010250780A1 (en) * 2009-05-18 2012-01-12 Panacea Biotec Ltd Universal influenza vaccine based on recombinant modified vaccinia Ankara virus (MVA)
US9095546B2 (en) * 2009-07-20 2015-08-04 National Health Research Institutes Human respiratory syncytial virus (RSV) vaccine
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012085936A2 (en) * 2010-12-20 2012-06-28 Panacea Biotech Ltd Recombinant respiratory syncytial virus plasmids and vaccines
US9125870B2 (en) * 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV

Also Published As

Publication number Publication date
LT2869841T (lt) 2021-11-25
SG11201408746XA (en) 2015-01-29
JP2015526403A (ja) 2015-09-10
WO2014006191A1 (en) 2014-01-09
MX365391B (es) 2019-05-31
IN2014KN03063A (da) 2015-05-08
HUE056675T2 (hu) 2022-02-28
MX2014016119A (es) 2015-09-23
AU2013285398A1 (en) 2015-02-05
ES2895070T3 (es) 2022-02-17
EA201492230A1 (ru) 2015-06-30
US20240091338A1 (en) 2024-03-21
CN104780937A (zh) 2015-07-15
IL236414A0 (en) 2015-02-26
WO2014005643A1 (en) 2014-01-09
CA2878367A1 (en) 2014-01-09
US20180256704A1 (en) 2018-09-13
BR112014033077A2 (pt) 2017-08-01
US20150209420A1 (en) 2015-07-30
ZA201500102B (en) 2017-09-27
JP6244358B2 (ja) 2017-12-06
KR20150038010A (ko) 2015-04-08
PT2869841T (pt) 2021-10-28

Similar Documents

Publication Publication Date Title
ZA201500102B (en) Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
HUS1700030I1 (hu) Véralvadásgátló-antidótumok
BR112015005783A2 (pt) análogos de glucagon.
LT3473714T (lt) Polipeptidai, pasižymintys transgalaktozilinimo aktyvumu
DK2822575T3 (da) Manipulerede, muterede antistof-interferon-fusionsmolekyler
LT3231801T (lt) Bipirazolo druska, kaip jak slopiklis
DK2831510T3 (da) Varmepumpesystem, der anvender latent varme
EP2934454C0 (en) Anti-dandruff composition
DK2571903T3 (da) Polymerer, der reagerer på stimuli, til oprensning af biomolekyler
EP2839106A4 (en) FINAL LONG, DISCONNECTED DRILLING HOLES
DK2867230T3 (da) Fremgangsmåde til fremstilling af 3,5-disubstitueret 1,2,4-oxadiazoler
GB2503742B (en) Collapsible ladder
EP2888965A4 (en) KIMONO
DK3524230T3 (da) Farmakologiske formuleringer, der omfatter ccr3-antagonister
BR112015010214A2 (pt) fogão, chapa, fogão tipo chapa
EP2878633A4 (en) curing composition
EP2879150A4 (en) SWITCH
FR2986872B1 (fr) .
DK2844546T3 (da) Ships ladder
FR2991627B1 (fr) Document de securite a haute durabilite
EP2878638A4 (en) curing composition
ITTO20130048A1 (it) Motociclo.
EP2878639A4 (en) Hardening composition
EP2839961A4 (en) INKJET PRINTER
FR3000112B1 (fr) Structure de securite.